MarkWide Research

Sale!

Global Pharmaceutical Contract Manufacturing Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: September, 2022
No of Pages: 168
Delivery Format: PDF+ Excel

$2,950.00

The global pharmaceutical contract manufacturing and research services market size was valued at USD 200.6 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.2% from 2022 to 2030. Cost-saving and time-saving benefits associated with the implementation of outsourcing are responsible for driving the market. The market participants are routinely investing in infrastructure, personnel, and technology in order to gain a greater share of the outsourcing revenue. The presence of end-to-end service providers that are engaged in offering value-added services for an integrated or risk-sharing business model is expected to bolster growth in this industry. The COVID-19 pandemic during its advent had temporally affected the supply chain, which is likely to have a negative effect on the market growth.

Changing product portfolio is also responsible for the growth of the service-based market. “One-stop-shop” offered by the CMOs for the promotion of a portfolio of a complete range of products is anticipated to influence the growth of CMOs. The larger CMOs are embracing the trend of moving and focusing on the niche areas of pharmaceutical development. They are focusing on the establishment of regulatory pathways for transgenic-based product development. However, the companies are willing to restrict outsourcing for the manufacturing of complex and big moieties. They are in an opinion of in-house production rather than outsourcing owing to the specific requirements. This, in turn, may act as a challenge for the market.

The COVID-19 pandemic has generated high demand for therapeutics and vaccines owing to the rising spread of the diseases worldwide. Owing to this, several companies had partnered with CMO to speed up the manufacturing of drugs. For instance, in December 2020, a CDMO, Recipharm signed an agreement with a pharmaceutical company Moderna. As per the agreement, Recipharm supported the fill-finish part of the Moderna COVID-19 vaccine for supply to countries outside the U.S. Many public organizations have also provided funding to support the research of COVID-19 vaccines. For instance, as of February 2022, the U.K. government invested USD 119.1 million to support the development of the Oxford/AstraZeneca COVID-19 vaccine. This is expected to have a positive impact on market growth.

Service Insights

The manufacturing segment held the largest revenue share of over 65.0% in 2021. This segment is further segmented into API/bulk drugs manufacturing, advanced drug delivery formulations, packaging, and finished dose formulations. API dominated the market in 2021 as a consequence of the rising demand for High Potency Active Pharmaceutical Ingredients (HPAPI). Market entities are engaged in the development of large-scale manufacturing facilities on a pilot as well as commercial scale.

Finished dose formulations are anticipated to expand at the fastest CAGR of 7.7% over the forecast period. Among these, solid formulations accounted for the largest revenue share in 2021 due to the higher outsourcing done for the powdered formulations. It is expected to witness gradual expansion in the coming years as it represents a significant share of the outsourcing of finished dose formulations. Solid dose manufacturing and oral delivery of new drug candidates, fixed-dose combinations, controlled release dosage forms, and reformulation of existing drugs are some of the factors likely to accelerate the growth of contract manufacturing of solid dosage formulations.

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

  • Competitive benchmarking
  • Historical data & forecasts
  • Company revenue shares
  • Regional opportunities
  • Latest trends & dynamics

Regional Insights

Asia Pacific dominated the market with a revenue share of over 40.0% in 2021 and is projected to grow at a significant rate over the forecast period. This growth is supported by a rise in the number of companies outsourcing projects in the developing economies of this region. In recent years, countries such as Singapore, China, and India have been observed as major players in the pharmaceutical industry owing to their expanding manufacturing capabilities. The cash-rich nature of the Asian companies is responsible for the captive nature of the contract manufacturing sector. The spout of significant investments by Asian CMOs is expected to result in exponential progress.

The Latin American market is anticipated to witness substantial growth over the forecast period as a consequence of the presence of established multinational players in this region. Major entities operating in Brazil are Novartis, Roche, and Pfizer. Latin America holds the potential for transforming into a global hub for the development and production of pharmaceutical products. Factors that are responsible for this transformation include the low cost of product development.

Key Companies & Market Share Insights

Market players are focusing on agreements, partnerships, collaborations, acquisitions, and other strategies to strengthen their market position. For instance, in January 2021, Boehringer Ingelheim entered into a planned collaboration as well as licensing agreement with Enara Bio for research and advancements in novel targeted cancer immunotherapies using Enara Bio’s Dark Antigen discovery platform. Similarly, in February 2021, Charles River Laboratories International, Inc. announced that it has signed a contract to acquire Cognate BioServices, Inc., a cell and gene therapy CDMO, for around USD 875 million. Some prominent players in the global pharmaceutical contract manufacturing and research services market include:

  • Catalent
  • Pharmaceutical Product Development LLC
  • AbbVie
  • Baxter BioPharma Solutions
  • Patheon
  • Grifols International, S.A.
  • Dalton Pharma Services
  • Boehringer Ingelheim Biopharmaceuticals GmbH
  • Lonza AG

Pharmaceutical Contract Manufacturing And Research Services Market Report Scope

Report AttributeDetails
Market size value in 2022USD 226.6 billion
Revenue forecast in 2030USD 395.2 billion
Growth rateCAGR of 7.2% from 2022 to 2030
Base year for estimation2021
Historical data2017 – 2021
Forecast period2022 – 2030
Quantitative unitsRevenue in USD billion and CAGR from 2022 to 2030
Report coverageRevenue forecast, company share, competitive landscape, growth factors and trends
Segments CoveredService, region
Regional scopeNorth America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country scopeU.S.; Canada; France; Germany; Italy; Spain; U.K.; India; China; Japan; Australia;  Brazil; Mexico; Colombia; Argentina; Chile; Venezuela; South Africa; Saudi Arabia
Key companies profiledCatalent; Pharmaceutical Product Development LLC; AbbVie; Baxter BioPharma Solutions; Patheon; Grifols International, S.A.; Dalton Pharma Services; Boehringer Ingelheim Biopharmaceuticals GmbH; Lonza AG

Segments Covered in the Report 

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global pharmaceutical contract manufacturing and research services market report on the basis of service and region:

  • Service Outlook (Revenue, USD Billion, 2018 – 2030)
    • Manufacturing
      • API/Bulk Drugs
      • Advanced Drug Delivery Formulations Packaging
      • Packaging
      • Finished Dose Formulations
        • Solid Formulations
        • Liquid Formulations
        • Semi-solid Formulations
      • Research
        • Oncology
        • Vaccines
        • Inflammation & Immunology
        • Cardiology
        • Neuroscience
        • Others
      • Regional Outlook (Revenue, USD Billion, 2018 – 2030)
        • North America
          • S.
          • Canada
        • Europe
          • Germany
          • France
          • Italy
          • Spain
          • K.
        • Asia Pacific
          • India
          • China
          • Japan
          • Australia
        • Latin America
          • Brazil
          • Mexico
          • Argentina
          • Colombia
          • Chile
          • Venezuela
        • Middle East & Africa
          • South Africa
          • Saudi Arabia

 

Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation & Scope
                       1.1.1 Service
                       1.1.2 Regional Scope
                       1.1.3 Estimates And Forecast Timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased Database
                       1.3.2 Gvr’s Internal Database
                       1.3.3 Secondary Sources
                       1.3.4 Primary Research
                       1.3.5 Details Of Primary Research
                   1.4 Information or Data Analysis
                       1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis (Model 1)
                       1.6.2 Volume Price Analysis (Model 2)
                   1.7 List of Secondary Sources
                   1.8 List of Primary Sources
                   1.9 List of Abbreviations
                   1.10 Objectives
                       1.10.1 Objective – 1
                       1.10.2 Objective – 2
                       1.10.3 Objective – 3
                       1.10.4 Objective – 4
Chapter 2 Executive Summary
                   2.1 Market Outlook
Chapter 3 Pharmaceutical Contract Manufacturing & Research Market: Variables, Trends, & Scope
                   3.1 Market Segmentation and Scope
                   3.2 Market Driver Analysis
                       3.2.1 Drug shortage driving demand for pharmaceutical development
                       3.2.2 Commercial success of biologics for clinical use
                       3.2.3 Lower manufacturing costs and improving economic condition of BRIC
                   3.3 Market Restraint Analysis
                       3.3.1 Limited outsourcing opted by big pharma companies
                       3.3.2 Regulatory issues pertaining to the drug approval
                   3.4 Penetration & Growth Prospect Mapping
                   3.5 Porter’s Five Forces Analysis
                   3.6 PESTEL Analysis
                   3.7 COVID-19 Analysis
Chapter 4 Pharmaceutical Contract Manufacturing & Research Market: Services Segment Analysis
                   5.1 Pharmaceutical Contract Manufacturing & Research Market: Market Share Analysis, 2021 & 2030
                   5.2 Manufacturing
                       5.2.1 Manufacturing market, 2018 – 2030 (USD Billion)
                       5.2.2 API/Bulk Drugs
                           5.2.2.1 API/Bulk Drugs market, 2018 – 2030 (USD Billion)
                       5.2.3 Advanced Drug Delivery Formulations
                           5.2.3.1 Advanced Drug Delivery Formulations market, 2018 – 2030 (USD Billion)
                       5.2.4 Packaging
                           5.2.4.1 packaging market, 2018 – 2030 (USD Billion)
                       5.2.5 Finished Dose Formulations
                           5.2.5.1 Finished Dose Formulations market, 2018 – 2030 (USD Billion)
                           5.2.5.2 Solid
                               5.2.5.2.1 Solid market, 2018 – 2030 (USD Billion)
                           5.2.5.3 Liquid
                               5.2.5.3.1 Liquid market, 2018 – 2030 (USD Billion)
                           5.2.5.4 Semi-solid formulations
                               5.2.5.4.1 Semi-solid formulations market, 2018 – 2030 (USD Billion)
                   5.3 Research
                       5.3.1 Research market, 2018 – 2030 (USD Billion)
                       5.3.2 Oncology
                           5.3.2.1 Oncology market, 2018 – 2030 (USD Billion)
                       5.3.3 Vaccines
                           5.3.3.1 Vaccines market, 2018 – 2030 (USD Billion)
                       5.3.4 Inflammation & Immunology
                           5.3.4.1 Inflammation & Immunology market, 2018 – 2030 (USD Billion)
                       5.3.5 Cardiology
                           5.3.5.1 Cardiology market, 2018 – 2030 (USD Billion)
                       5.3.6 Neuroscience
                           5.3.6.1 Neuroscience market, 2018 – 2030 (USD Billion)
                       5.3.7 Others
                           5.3.7.1 Others market, 2018 – 2030 (USD Billion)
Chapter 6 Pharmaceutical Contract Manufacturing & Research Market: Regional Analysis
                   6.1 Pharmaceutical Contract Manufacturing & Research Market: Market Share Analysis, 2021 & 2030
                   6.2 North America
                       6.2.1 North America Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.2.2 U.S.
                           6.2.2.1 U.S. Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.2.3 Canada
                           6.2.3.1 Canada Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                   6.3 Europe
                       6.3.1 Europe Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.3.2 Germany
                           6.3.2.1 Germany Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.3.3 France
                           6.3.3.1 France Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.3.4 Italy
                           6.3.4.1 Italy Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.3.5 Spain
                           6.3.5.1 Spain Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.3.6 U.K.
                           6.3.6.1 U.K. Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                   6.4 Asia Pacific
                       6.4.1 Asia Pacific Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.4.2 China
                           6.4.2.1 China Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.4.3 India
                           6.4.3.1 India Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.4.4 Japan
                           6.4.4.1 Japan Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.4.5 Australia
                           6.4.5.1 Australia Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                   6.5 Latin America
                       6.5.1 Latin America Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.5.2 Brazil
                           6.5.2.1 Brazil Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.5.3 Mexico
                           6.5.3.1 Mexico Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.5.4 Argentina
                           6.5.4.1 Argentina Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.5.5 Colombia
                           6.5.5.1 Colombia Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.5.6 Chile
                           6.5.6.1 Chile Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.5.7 VENEZUELA
                           6.5.7.1 venezuela Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                   6.6 MEA
                       6.6.1 MEA Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.6.2 South Africa
                           6.6.2.1 South Africa Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
                       6.6.3 Saudi Arabia
                           6.6.3.1 Saudi Arabia Pharmaceutical Contract Manufacturing & Research Market, 2018 – 2030 (USD Billion)
Chapter 7 Competitive Landscape
                   7.1 Strategy Framework
                   7.2 Market Participation Categorization
                   7.3 Company Profiles
                       7.3.1 Boehringer Ingelheim GmbH
                           7.3.1.1 Company overview
                           7.3.1.2 Financial performance
                           7.3.1.3 Product benchmarking
                           7.3.1.4 Strategic initiatives
                       7.3.2 Lonza
                           7.3.2.1 Company overview
                           7.3.2.2 Financial performance
                           7.3.2.3 Product benchmarking
                           7.3.2.4 Strategic initiatives
                       7.3.3 Grifols S.A
                           7.3.3.1 Company overview
                           7.3.3.2 Financial performance
                           7.3.3.3 Product benchmarking
                           7.3.3.4 Strategic initiatives
                       7.3.4 Jubilant Life Sciences Limited
                           7.3.4.1 Company overview
                           7.3.4.2 Financial performance
                           7.3.4.3 Product benchmarking
                           7.3.4.4 Strategic initiatives
                       7.3.5 Pfizer, Inc.
                           7.3.5.1 Company overview
                           7.3.5.2 Financial performance
                           7.3.5.3 Product benchmarking
                           7.3.5.4 Strategic initiatives
                       7.3.6 Charles River Laboratories International, Inc
                           7.3.6.1 Company overview
                           7.3.6.2 Financial performance
                           7.3.6.3 Product benchmarking
                           7.3.6.4 Strategic initiatives
                       7.3.7 Albany Molecular Research, Inc.
                           7.3.7.1 Company overview
                           7.3.7.2 Product benchmarking
                           7.3.7.3 Strategic initiatives
                       7.3.8 Covance, Inc. (LabCorp)
                           7.3.8.1 Company overview
                           7.3.8.2 Financial performance
                           7.3.8.3 Product benchmarking
                       7.3.9 IQVIA
                           7.3.9.1 Company overview
                           7.3.9.2 Financial performance
                           7.3.9.3 Product benchmarking
                           7.3.9.4 Strategic initiatives
                       7.3.10 Baxter BioPharma Solutions
                           7.3.10.1 Company overview
                           7.3.10.2 Financial performance
                           7.3.10.3 Product Benchmarking
                           7.3.10.4 Strategic initiatives
                       7.3.11 Aenova Holding GmbH
                           7.3.11.1 Company overview
                           7.3.11.2 Product Benchmarking
                       7.3.12 Vetter Pharma
                           7.3.12.1 Company Overview
                           7.3.12.2 Product benchmarking
                       7.3.13 Valeant Pharmaceuticals International Inc.
                           7.3.13.1 Company Overview
                           7.3.13.2 Financial performance
                           7.3.13.3 Product benchmarking
                       7.3.14 Ligand Pharmaceuticals, Inc.
                           7.3.14.1 Company Overview
                           7.3.14.2 Financial performance
                           7.3.14.3 Product benchmarking
                           7.3.14.4 Strategic initiatives
                       7.3.15 Pharmaceutical Product Development, LLC
                           7.3.15.1 Company Overview
                           7.3.15.2 Financial performance
                           7.3.15.3 Product benchmarking
                           7.3.15.4 Strategic initiatives
                       7.3.16 Recipharm AB.
                           7.3.16.1 Company Overview
                           7.3.16.2 Financial performance
                           7.3.16.3 Product benchmarking
                           7.3.16.4 Strategic initiatives
                       7.3.17 AbbVie, Inc.
                           7.3.17.1 Company Overview
                           7.3.17.2 Financial performance
                           7.3.17.3 Product benchmarking
                           7.3.17.4 Strategic initiatives
                       7.3.18 Famar Health Care Services
                           7.3.18.1 Company Overview
                           7.3.18.2 Product benchmarking
                           7.3.18.3 Strategic initiatives
                       7.3.19 Catalent Pharma Solutions
                           7.3.19.1 Company Overview
                           7.3.19.2 Financial performance
                           7.3.19.3 Product benchmarking
                           7.3.19.4 Strategic initiatives
                       7.3.20 West Pharmaceutical Services, Inc.
                           7.3.20.1 Company Overview
                           7.3.20.2 Financial performance
                           7.3.20.3 Product benchmarking
                           7.3.20.4 Strategic initiatives

Major Companies

  • Catalent
  • Pharmaceutical Product Development LLC
  • AbbVie
  • Baxter BioPharma Solutions
  • Patheon
  • Grifols International, S.A.
  • Dalton Pharma Services
  • Boehringer Ingelheim Biopharmaceuticals GmbH
  • Lonza AG

Segmentation

  • Service Outlook (Revenue, USD Billion, 2018 – 2030)
    • Manufacturing
      • API/Bulk Drugs
      • Advanced Drug Delivery Formulations Packaging
      • Packaging
      • Finished Dose Formulations
        • Solid Formulations
        • Liquid Formulations
        • Semi-solid Formulations
      • Research
        • Oncology
        • Vaccines
        • Inflammation & Immunology
        • Cardiology
        • Neuroscience
        • Others

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF